newsfilter
← Latest News
GlobeNewswire·

ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income(1) of $161 Million,